Gilead Reports Positive Trial Data for HIV, Liver Drugs

Week-52 results from two studies show high persistence with a twice-yearly HIV prevention injection and strong liver marker response to Livdelzi.

Updated on Nov. 9, 2026 in Biotech

Clean editorial illustration of a glass vial and syringe beside a small pair of capsules on a cream field, contrasting a single dose with a daily regimen.
Gilead Sciences reported 52-week trial results showing participants persisted far more consistently with a twice-yearly lenacapavir HIV prevention injection than with daily oral pills. AI Illustration. Upload story photo >

Gilead Sciences released 52-week results from the Phase 2 PURPOSE 5 study of its twice-yearly lenacapavir HIV prevention injection and from the Phase 3 IDEAL study of Livdelzi for primary biliary cholangitis. The PURPOSE 5 trial enrolled 267 participants across the U.K. and France and compared the injection with daily oral emtricitabine/tenofovir disoproxil fumarate.

Why it matters

The PURPOSE 5 results suggest participants stayed on the twice-yearly injection far more consistently than on daily pills, and no HIV infections occurred in the lenacapavir cohort over 52 weeks. The IDEAL data show a larger share of Livdelzi patients reaching alkaline phosphatase normalization and fewer serious adverse events than placebo.

Week-52 results from the randomized PURPOSE 5 study showed 85.6% of lenacapavir recipients maintained strict persistence versus 46.3% on daily oral pills. In the IDEAL study, 75.4% of Livdelzi patients achieved alkaline phosphatase normalization versus 16.1% on placebo at Week 52.

The players

Gilead Sciences

Gilead Sciences is a U.S.-based biopharmaceutical company that develops antiviral and liver disease therapies, including its HIV treatments and Livdelzi.

The details

In PURPOSE 5, one participant in the oral group acquired HIV after taking fewer than two doses weekly, while no infections occurred in the lenacapavir group. In the IDEAL study of Livdelzi (seladelpar), serious adverse events occurred in 3.1% of treated participants versus 12.9% on placebo, and 52.3% met the composite goal after one month versus 6.5% on placebo.

Timeline

  1. Week 52 PURPOSE 5 data were released on a Friday.

  2. Detailed 52-week IDEAL study findings for Livdelzi were released on a Thursday.

  3. Gilead shares traded at $169.11 at the time of publication on a Monday.

Roadmap

Twice-yearly lenacapavir is being evaluated as an alternative to daily oral PrEP, which requires sustained daily adherence. The 52-week PURPOSE 5 persistence gap between the injection and daily pills adds to the case for long-acting HIV prevention options.

For people who take daily HIV prevention pills, the persistence data suggest a twice-yearly injection could reduce how often they need to remember a dose. Clinicians and patients will need to weigh availability and approval status before any change in prevention options.

The takeaway

Long-acting HIV prevention may improve adherence for people who struggle with daily pills, though the data come from a relatively small trial of 267 participants. Readers should track regulatory decisions before assuming access.

Further reading

Explore more biotech coverage for context on drug development and clinical trial results.

Source note: This article includes information reported by Benzinga.